WO2019087207A2 - Composition à base d'herbes pour le traitement et la gestion d'un dysfonctionnement de la thyroïde et son procédé de préparation - Google Patents

Composition à base d'herbes pour le traitement et la gestion d'un dysfonctionnement de la thyroïde et son procédé de préparation Download PDF

Info

Publication number
WO2019087207A2
WO2019087207A2 PCT/IN2018/050691 IN2018050691W WO2019087207A2 WO 2019087207 A2 WO2019087207 A2 WO 2019087207A2 IN 2018050691 W IN2018050691 W IN 2018050691W WO 2019087207 A2 WO2019087207 A2 WO 2019087207A2
Authority
WO
WIPO (PCT)
Prior art keywords
amount
composition
bhasma
preparation
thyroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2018/050691
Other languages
English (en)
Other versions
WO2019087207A3 (fr
Inventor
M Vijayabhanu SHETTY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Muniyal Ayurvedic Research Centre
Original Assignee
Muniyal Ayurvedic Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Muniyal Ayurvedic Research Centre filed Critical Muniyal Ayurvedic Research Centre
Publication of WO2019087207A2 publication Critical patent/WO2019087207A2/fr
Publication of WO2019087207A3 publication Critical patent/WO2019087207A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/241—Lead; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/264—Aristolochia (Dutchman's pipe)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Definitions

  • Thyroid glands the endocrine glands siting in the neck wrapping around the wind pipe, play a critical role in metabolic and cardiovascular activities of the body. Thyroid glands are capable of regulating these vital activities through hormones viz. Triiodothyronine (T3) and Thyroxine (T4).
  • T3 Triiodothyronine
  • T4 Thyroxine
  • hypothalamus and pituitary glands are crucial in the functioning of the thyroid glands. They communicate with each other and the thyroid glands in order to maintain T3 and T4 levels.
  • TRH TSH releasing hormone
  • TSH thyroid- stimulating hormone
  • T3 and T4 are indicative of an ill functioning thyroid gland. Further, a defective pituitary gland may also lead to thyroid hormone imbalance. Regardless of the reason, the over or under production of these Thyroid hormones lead to thyroid disorders.
  • Hyperthyroidism is a case of increased levels of thyroid hormones, the causes of which include Graves' disease, tumors of the thyroid glands and toxic adenomas of thyroid glands. Reduced levels of thyroid hormones is a case of Hypothyroidism which may be caused by Hashimoto's disease, Iodine deficiency, etc. Such thyroid hormone imbalance can lead to hypertension, heart failure, etc.
  • T3 and T4 imbalance are known. These methods include hormone supplementation, anti-thyroid drugs, surgery, etc. However, such allopathic interventions have been known to have side effects.
  • the principal object of the embodiments disclosed herein is to provide a method of treating Thyroid dysfunction and associated complications.
  • a second object of the embodiments disclosed herein is to provide a method of management of Thyroid dysfunction and associated complications.
  • Another object of the embodiments disclosed herein is to provide herbal composition and a method for its preparation.
  • Fig.1(a) depicts a flowchart for the preparation of Swarna Makshika Bhasma, according to the various embodiments herein;
  • FIG.1(b) depicts a flowchart for the preparation of Abhraka Bhasma, according to embodiments as disclosed herein;
  • Fig.1(c) depicts a flowchart for the preparation of Loha Bhasma, according to embodiments as disclosed herein;
  • Fig.1(d) depicts a flowchart for the preparation of Trivanga Bhasma, according to embodiments as disclosed herein;
  • Fig.1(e) depicts a flowchart for the preparation of Pravala Bhasma, according to embodiments as disclosed herein;
  • Fig.2 depicts a flowchart for the preparation of fortified tablets, according to embodiments as disclosed herein.
  • the embodiments herein achieve a herbal composition of therapeutic value, and a process for the preparation of the composition.
  • the herbal composition disclosed herein is useful in the treatment and management of Thyroid dysfunction and associated complications.
  • the composition, disclosed in the various embodiments herein may be used to treat hypothyroidism, hyperthyroidism and any complications associated with thyroid. It has been observed that the Disclosed composition may also be instrumental in the management of autoimmune thyroiditis. Accordingly, the embodiments disclosed herein achieve a method for the treatment of Thyroid dysfunction and associated complications.
  • the Disclosed composition in various embodiments, may be used as a main line of treatment or as supportive medication in addition to other line of medication such as allopathy.
  • the disclosed embodiments herein provide a herbal composition having a combination of selected herbs and minerals.
  • the herbal composition includes herbs and minerals.
  • the herbal composition includes a herbs, minerals and a suitable excipient.
  • the composition includes the herbs Bauhinia variegata, Crataeva nurvala and Commiphora mukul (also referred to as Guggulu), or their extracts, or the active ingredients extracted from these herbs.
  • the composition further includes at least one of the herbs selected from Emblica officinalis, Terminalia chebula, Terminalia bellerica, Zingiber officinale, Piper nigrum, Piper longum, Cinnamomum zeylanica, Elettaria cardamomum, Cinnamomum tamala, Glycerrhiza glabra, Boerhavia diffusa, Adhtatoda vasica, Vinca rosea, Withania somnifera, Sida cordifolia, Tinospora cordifolia, Ocimum sanctum, Curcuma longa, Moringa oleifera, Aristolochia indica, Azadirachta indica and Eclipta alba;
  • the composition may include specific parts of the herb (also referred as herb component) such as roots, fruits, bark, stem, leaves, rhizome, etc.
  • the composition includes stem bark of Bauhinia variegata, Crataeva nurvala, Cinnamomum zeylanica, Moringa oleifera and Azadirachta indica; oleo gum resin of Commiphora mukul, fruits of Emblica officinalis, Terminalia chebula, Terminalia bellerica, Piper nigrum and Piper longum, rhizome of Zingiber officinale, Glycerrhiza glabra and Curcuma longa; seeds of Elettaria cardamomum; leaves of Cinnamomum tamala, Vinca rosea and Ocimum sanctums; roots of Boerhavia diffusa, Adhtatoda vasica, Aristolochia indica, Withania somnifera and
  • the composition includes Bauhinia variegata in an amount ranging from 10 to 14 wt%, Crataeva nurvala in an amount ranging from 10 to 14 wt%, and Commiphora mukul in an amount ranging from 8 to 12 wt%, of the total weight of the composition.
  • the composition may further include Emblica officinalis in an amount ranging from 2 to 6 wt%, Terminalia chebula in an amount of ⁇ 3wt%, Terminalia bellerica in an amount of ⁇ 3wt%, Zingiber officinale in an amount of ⁇ 3wt%, Piper nigrum in an amount of ⁇ 3wt%, Piper longum in an amount of ⁇ 3wt%, Cinnamomum zeylanica in an amount of ⁇ 3wt%, Elettaria cardamomum in an amount of ⁇ 3wt%, Cinnamomum tamala in an amount of ⁇ 3wt%, Glycerrhiza glabra in an amount of ⁇ 3wt%, Boerhavia diffusa in an amount of ⁇ 3wt%, Adhtatoda vasica in an amount of ⁇ 3wt%, Vinca rosea in an amount of ⁇ 3wt%, Withania somnifera
  • the herb component of the herbs, disclosed herein, maybe included in the composition in any form that is generally known in the field.
  • the herb component may be processed to form extracts, dried, powdered, pelleted, concentrated, etc.
  • the herb components are dried and powdered which is further incorporated into the composition.
  • the herb component may be an aqueous starch extract.
  • the composition includes minerals in the form of Bhasmas or calcined preparations such as Swarna Makshika bhasma, Abhraka bhasma, Loha bhasma, Trivanga bhasma, and Pravala bhasma.
  • the composition may also include atleast one mineral selected from a group consisting of mica, lead, tin, zinc, coral, iron and copper pyrite.
  • the bhasmas along with the herbs form bioavailable herbal complexes which are useful in treating Thyroid dysfunction and associated complications.
  • the composition includes Shilajit.
  • the herbal composition it is also within the scope of claims provided herewith for the herbal composition to include, as a substitute or additionally, other similar calcined preparations or minerals without otherwise deterring from the intended function of the herbal composition.
  • the composition includes Swarna Makshika bhasma in an amount of ⁇ 2wt%, Abhraka bhasma in an amount of ⁇ 2wt%, Loha bhasma in an amount of ⁇ 2wt%, Trivanga bhasma in an amount of ⁇ 2wt% and Pravala bhasma in an amount of ⁇ 2wt%.
  • the mineral component includes shilajit in an amount in the range of 2 to 6 wt%.
  • the Disclosed composition may further include a suitable excipient.
  • suitable excipients may include solvents, binders, lubricants, herbal carriers, oils and salts that are generally known in the art.
  • the excipient includes acacia gum.
  • the amount of herb and mineral that may be included in the various embodiments of the disclosed composition may each be in the range of 0 to 14wt%.
  • the composition includes Bauhinia variegata (10 to 14 wt%), Crataeva nurvala (10 to 14 wt%), Commiphora mukul (8 to 12 wt%) and shilajit (2 to 6 wt%), of the total weight of the composition.
  • the composition includes Bauhinia variegata (10 to 14 wt%), Crataeva nurvala (10 to 14 wt%) and Commiphora mukul (8 to 12 wt%); atleast one of Emblica officinalis ( 2 to 6 wt%), Terminalia chebula ( ⁇ 3wt%), Terminalia bellerica ( ⁇ 3wt%), Zingiber officinale ( ⁇ 3wt%), Piper nigrum ( ⁇ 3wt%), Piper longum ( ⁇ 3wt%), Cinnamomum zeylanica ( ⁇ 3wt%), Elettaria cardamomum ( ⁇ 3wt%), Cinnamomum tamala ( ⁇ 3wt%), Glycerrhiza glabra ( ⁇ 3wt%), Boerhavia diffusa ( ⁇ 3wt%), Adhtatoda vasica ( ⁇ 3wt%), Vinca rosea ( )
  • the composition includes Bauhinia variegata (10 to 14 wt%), Crataeva nurvala (10 to 14 wt%) and Commiphora mukul (8 to 12 wt%); atleast one of Emblica officinalis ( 2 to 6 wt%), Terminalia chebula ( ⁇ 3wt%), Terminalia bellerica ( ⁇ 3wt%), Zingiber officinale ( ⁇ 3wt%), Piper nigrum ( ⁇ 3wt%), Piper longum ( ⁇ 3wt%), Cinnamomum zeylanica ( ⁇ 3wt%), Elettaria cardamomum ( ⁇ 3wt%), Cinnamomum tamala ( ⁇ 3wt%), Glycerrhiza glabra ( ⁇ 3wt%), Boerhavia diffusa ( ⁇ 3wt%), Adhtatoda vasica ( ⁇ 3wt%), Vinca rosea ( )
  • the composition includes Bauhinia variegata (10 to 14 wt%), Crataeva nurvala (10 to 14 wt%), Commiphora mukul (8 to 12 wt%); ateast one of Emblica officinalis ( 2 to 6 wt%), Terminalia chebula ( ⁇ 3wt%), Terminalia bellerica ( ⁇ 3wt%), Zingiber officinale ( ⁇ 3wt%), Piper nigrum ( ⁇ 3wt%), Piper longum ( ⁇ 3wt%), Cinnamomum zeylanica ( ⁇ 3wt%), Elettaria cardamomum ( ⁇ 3wt%), Cinnamomum tamala ( ⁇ 3wt%), Glycerrhiza glabra ( ⁇ 3wt%), Boerhavia diffusa ( ⁇ 3wt%), Adhtatoda vasica ( ⁇ 3wt%), Vinca rosea ( ⁇
  • the amount of gum acacia may be any amount suitable to perform the activity of an excipient.
  • the composition may include gum acacia in an amount in the range of 8 to 12 wt.%.
  • the herbal composition disclosed herein may be formulated in various dosage forms such that it is suitable for oral administration.
  • the herbal composition may be in the form of tablets, pellets, lozenges, granules, capsules, solutions, emulsions, suspensions, or any other form suitable for use.
  • the herbal composition is formulated in the form of tablets, preferably 500 mg tablets.
  • Table 1A depicts the quantities of each ingredient in a 500 mg tablet. All weight percentages provided herein are based on the total weight of the composition.
  • the tablet for treating cancer.
  • the tablet is a 500mg tablet having herb component, mineral component and excipient as depicted in Table 1.
  • Each 500 mg tablet includes:
  • the disclosed composition is a blackish brown biconvex shaped tablet having the characteristics as depicted in Table 2.
  • Table 2 The invention is further described by reference to the following table by way of illustration only, and should not be construed to limit the scope of the present invention. It will be apparent to those skilled in the art that many modifications may be practiced without departing from the scope of the present invention. ⁇ 00391 Table 2:
  • the method includes,
  • the process further includes mixing the obtained composition with an excipient such as gum acacia and grinding for a period of 1 to 3 hours; and drying of the obtained mass at a temperature in the range of 40 to 60 degree Celsius. Further, the obtained mass may be subjected to wet granulation followed by punching into 500 mg tablets.
  • an excipient such as gum acacia and grinding for a period of 1 to 3 hours
  • the bhasmas include atleast one of Abhraka Bhasma, Pravala Bhasma, Loha Bhasma, Trivanga Bhasma and Swarna Makshika Bhasma.
  • the mixture of bhasmas, guggulu and shilajit may be in semi solid form.
  • the levigation may be performed for a duration of around 3 hours.
  • the finely powdered herbs include finely powdered dry stem bark of Bauhinia variegata, Crataeva nurvala, Cinnamomum zeylanica, Moringa oleifera and Azadirachta indica; fruits of Emblica officinalis, Terminalia chebula, Terminalia bellerica, Piper nigrum and Piper longum, rhizome of Zingiber officinale, Glycerrhiza glabra and Curcuma longa; seeds of Elettaria cardamomum; leaves of Cinnamomum tamala, Vinca rosea and Ocimum sanctum, roots of Boerhavia diffusa, Adhtatoda vasica, Aristolochia indica, Withania somnifera and Sida cordifolia; aqueous starch extract of stem and dry stem of Tinospora cordifolia and whole plant of Eclipta alba.).
  • the grinding decoction is a decoction of herbs (also referred as grinding herbs) that may facilitate grinding.
  • the grinding decoction includes a decoction of at least one herb selected from a list consisting of: Embilca officinalis, Terminalia chebula, Terminalia bellerica, Crataeva nurvala, Bauhinia variegate, Steriospermum suaveolens, Premna mucronate, Gmelina arborea, Aegle marmelos, Oroxylum indicum, Desmodium gangeticum, Uraria picta, Solanum indicum, Solanum xanthocarpum, Tribulus terrestris, Vinca rosea, Cynadon dactylon, Rubia cordifolia, Acacia catechu, Adhatoda vasica, Eclipta alba, Moringa oleifera, Cuminum cyminum, Mimosa pudica, Calotropis procera, Si
  • the decoction may be obtained by any method of decocting generally known in the field.
  • the method of preparation of grinding decoction includes:
  • soaking the grinding herbs For example, soaking powdered dry fruit of Embilca officinalis, Tribulus terrestris, Terminalia chebula and Terminalia bellerica; dry stem bark of Crataeva nurvala, Moringa oleifera and Bauhinia variegate; dry roots of Steriospermum suaveolens, Calotropis procera, Sida cordifolia, Rubia cordifolia, Premna mucronate, Gmelina arborea, Aegle marmelos, Solanum indicum and Oroxylum indicum; dry plant of Desmodium gangeticum, Uraria picta and Solanum xanthocarpum, fresh leaves of Vinca rosea, Ocimum sanctum, Murraya koeinigii and Adhatoda vasica; fresh whole plant of Cynadon dactylon, Trichosanthes dioica and Eclipta alba; dry heartwood of Acacia cate
  • soaking may be performed by soaking the grinding herbs in 16 parts of water overnight.
  • concentrating may be performed by boiling at high temperature, preferably about 80°C to 85°C, until l/8th of the liquid remains. Concentration may be confirmed with the help of Brix meter.
  • grinding decoction is added.
  • grinding is continued for about 72 hours, preferably at about 120 rpm, to obtain a ground mass.
  • gum acacia may be added to the obtained composition by dissolving in the grinding decoction while continuing grinding for 3 hours to obtain a semisolid mass.
  • the method further includes drying the obtained mass at about 60 degree Celsius, preferably in a hot air oven, to obtain a composition disclosed in the various embodiments herein.
  • the method may further include wet granulating and punching of the obtained mass to obtain 500mg tablets.
  • Fig. 2 depicts a flowchart for the preparation of fortified tablets. Table 2 depicts the Herb ingredients required for grinding (grinding herbs) in one of the preferred embodiments.
  • the bhasmas that are used in the various embodiments of the disclosed herbal composition may be prepared by methods that are generally known in the field.
  • Bhasmas may be prepared by selecting genuine standard minerals as starting material such as Swarna makshika, steel iron, green vitriol etc; drying in a hot air oven; purifying the mineral by triturating, quenching, boiling, etc.; triturating the purified material with herbal decoction/juice; preparing into discs; drying of discs; preparing sharavasam puta, subjecting Sharavasam puta to Gaja puta, and powdering of discs once cooled.
  • the method is repeated 30 times till bhasma is obtained.
  • the starting materials used in the preparation of bhasmas may include standard minerals generally used in the field.
  • the preparation of Swarna makshika Bhasma includes Swarna makshika (Chalcopyrite) as the starting material.
  • Fig. 1(a) depicts a flowchart for the preparation of Swarna makshika Bhasma using Swarna makshika as the starting material.
  • the preparation of Abhraka Bhasma includes mica as the starting material.
  • Fig.1(b) depicts a flowchart for the preparation of Abhraka Bhasma using mica as the starting material.
  • the preparation of Loha Bhasma includes steel iron as the starting material.
  • Fig.1(c) depicts a flowchart for the preparation of Loha Bhasma using steel iron as the starting material.
  • the preparation of Trivanga Bhasma includes alloy of tin, lead and zinc as the starting material.
  • Fig.1(d) depicts a flowchart for the preparation of Trivanga Bhasma using alloy of tin, lead and zinc as the starting material.
  • the preparation of Pravala Bhasma includes coral as the starting material.
  • Fig.1(e) depicts a flowchart for the preparation of Pravala Bhasma using coral as the starting material.
  • the purification, or shodhana, of the mineral may be performed by generally known methods in the field.
  • the purification may be by mixing the starting material with rock salt and lemon juice such as that in the preparation of Swarna makshika Bhasma.
  • the purification may be by quenching the mineral in Triphala decoction such as that in the preparation of Loha Bhasma.
  • the purification may be by quenching in Cow's milk such as that in the preparation of Abhraka Bhasma.
  • the purification may be by melting and pouring in lime water, preferably seven times, such as that in the preparation of Trivanga Bhasma.
  • the purification may be by boiling in alkaline solution of Barilla such as that in the preparation of Pravala Bhasma.
  • the herbal decoction/juice used may be any herbal decoction/juice that is generally used for triturating in the preparation of bhasmas.
  • the herbal decoction/juice may include triphala, lemon juice, Gomutra(cow' s urine) etc.
  • the herbal decoction used in the preparation of Swarna Makshika bhasma specifically includes Nimbu Swarasa (Lemon juice) and Kulatha Kwatha (Decoction of Dolichos biflorus).
  • the herbal decoction used in the preparation of Abhraka Bhasma specifically includes Emblica officinalis, Terminalia chebula, Terminalia bellerica, Cyperus rotundus, Ficus bengalensis and Curcuma longa.
  • Table 4A depicts the list of herbs required for the herbal decoction used in trituration while preparing Abhraka Bhasma.
  • Table 4A - Herbal decoction used for trituration while preparing Abhraka Bhasma includes the following:
  • the herbal juice useful in the preparation of Abhraka Bhasma specifically includes Cassia occidentalis, Piper betle, Adhatoda vasica, Emblica officinalis, Alternathera sessilis, Amaranthus spinosus, Ricinus communis and Calotropis precera, wherein it is.
  • Table 4B depicts the list of herbs required for the herbal juice used in trituration while preparing Abhraka Bhasma.
  • Table 4B - Herbal juice used in trituration while preparing Abhraka Bhasma includes the following:
  • the herbal decoction useful in the preparation of Loha Bhasma specifically includes Emblica officinalis, Terminalia chebula, Terminalia bellerica, Crataeva nurvala, Boerhavia diffua, Bauhinia variegate and Cow urine.
  • Table 4C depicts the list of herbs required for the herbal decoction used in trituration while preparing Loha Bhasma.
  • the herbal decoction includes Triphala Kashaya (decoction of fruits of Terminalia chebula, Terminalia bellerica and Emblica officinalis), wherein it is useful in the preparation of Loha Bhasma.
  • Table 4C - Herbal decoction used in trituration while preparing Loha Bhasma includes the following:
  • the herbal decoction used in the preparation of Trivanga Bhasma specifically includes Emblica officinalis, Terminalia chebula, Terminalia bellerica and Curcuma Longa.
  • Table 4D depicts the list of herbs required for the herbal decoction used in trituration while preparing Trivanga Bhasma.
  • Table 4D Herbal decoction used in trituration while preparing Trivanga Bhasma includes the following:
  • the herbal juice used in the preparation of Trivanga Bhasma specifically includes Aloe vera and Aegle marmelos.
  • Table 4E depicts the list of herbs required for the herbal juice used in trituration while preparing Trivanga Bhasma.
  • Table 4E - Herbal juice used in trituration while preparing Trivanga Bhasma includes the following:
  • the herbal juice used in the preparation of Pravala Bhasma specifically includes Aloe vera, Asparagus racemosus, Sesbania sesban and Cow milk.
  • Table 4F depicts the list of herbs required for the herbal juice used in trituration while preparing Pravala Bhasma.
  • Table 4F - Herbal juice used in trituration while preparing Pravala Bhasma includes the following:
  • the raw material used is Swarna Makshika i.e. Copper pyrite. Copper pyrite which looks yellow with iridescent tarnish having greenish black streak, uneven fracture, metallic luster, brittle tenacity, opaque with hardness between 3 and 4, specific gravity between 3.4 and 3.7 is selected.
  • a sample of Swarna Makshika with, Copper: not ⁇ 5%, Iron: not ⁇ 20%, Sulphur: not ⁇ 12% is selected.
  • the selected raw material is washed with demineralized water to remove dirt and dried in hot air oven at about 50°C.
  • the raw material is then subjected to purification (Shodhana).
  • the Swarna makshika is powdered in an iron mortar with an iron pestle.
  • a clean and dry iron pan is then heated on a charcoal furnace onto which the powdered Swarna makshika and Saindhava Lavana (Rock salt) of about 1/3 the amount of Swarna Makshika, is poured.
  • This mixture is subjected to intense heat with frequent addition of lemon juice till the liberation of sulfur fumes stopped and it turns red.
  • the process is completed in 3 days and the final product called Shodhita Swarna makshika obtained.
  • This powder is added with water, mixed well, water is decanted to remove excess of salt.
  • This powder is then dried under sun or in a hot air oven at about 50°C to get a powder.
  • the powder obtained is the purified Swarna Makshika.
  • the purified Swarna Makshika powder is triturated with lemon juice for about six hours till a soft homogenous paste or dough is obtained.
  • the dough obtained is prepared into discs of 0.5cm thickness and 2.5 cm diameter.
  • the discs are dried under Sun or in a hot air oven at about 50 ° C.
  • the dried discs are spread as a layer in an earthen saucer (Sharava). It is closed with another earthen saucer.
  • the joint between the earthen saucers is sealed with mud plasters and dried to get a capsule (Sharava samputa).
  • the dried earthen capsule containing the discs is subjected to heat using Gaja Puta (here, in a pit of 56.26x56.25x56.25 cubic cm, 250 cowdungs of standard size are filled) earthen capsule is placed on it.
  • the vacant space is again filled with 125 cowdungs and lit with fire (here, specific quantum and pattern of heating is provided.).
  • the saucers are allowed to cool. After self-cooling (cooling by itself, without any external aid), the earthen saucer capsule is carefully collected, seal is removed, saucers separated and the material inside is collected.
  • the collected partially incinerated Swarna Makshika discs are powdered and levigated with lemon juice. It is then again prepared into discs, dried, encapsulated and subjected to heat. This cycle from grinding with lemon juice till heating is repeated atleast 10 times or till the Bhasma is properly prepared which is ascertained by specific generally known tests.
  • the obtained Dhanyabhraka is now incinerated (Marana).
  • the Dhanyabhraka is levigated in Mortar & Pestle with specific decoction/juice (provided in Table 4A& Table 4B) in equal quantity by weight for at least 6 hrs till a homogeneous paste was formed, from which pellets(discs) are made of uniform size & shape (0.5x2.5 cm).
  • Discs are dried under Sun or /in hot air oven at about 50 ° C. Dried discs are spread as a layer in an earthen saucer (Sharava). It is then closed with another earthen saucer.
  • the joint between the earthen saucers is sealed with mud plasters and dried to get a capsule (Sharava samputa).
  • Dried earthen capsule containing the discs is subjected to heat using Gaja Puta (here, in a pit of 56.26x56.25x56.25 cubic cm, 250 cow dungs of standard size are filled) earthen capsule is placed on it.
  • Gaja Puta here, in a pit of 56.26x56.25x56.25 cubic cm, 250 cow dungs of standard size are filled
  • earthen capsule is placed on it.
  • Vacant space is again filled with 125 cowdungs and lit with fire (here, specific quantum and pattern of heating is provided).
  • the raw material is then subjected to purification by Samanya shodhana process and Vishesha shodhana process.
  • specific quantity of raw material Fe turning
  • tila taila sesame oil
  • takra buttermilk
  • Gomutra cow's urine
  • kanji sour rice gruel
  • kulattha kwatha decoction of horse gram
  • This quenching process is repeated for seven times consecutively in tila taila followed by seven times consecutively in takra, gomutra, kanji, and kulattha kwatha by using fresh media every time.
  • material is filtered by Fe mesh and dried under sunlight. The material obtained at this stage is called samanya shodhita loha.
  • the loha churna (coarse powder of Fe turning) obtained at this stage is called vishesha shodhita loha.
  • the Triphala kwatha was prepared by heating equal quantity of Triphala to vishesha shodhita loha churna with two parts of water and reduced to l/4th of original volume. This Triphala kwatha was added to loha obtained after vishesha shodhana and allowed to dry under sunlight.
  • Sthalipaka Heating in vessel using fire
  • Triphala kwatha is prepared by taking Triphala, 3 parts of loha obtained after bhanupaka, and 16 parts of water was added to it.
  • the whole material was boiled in a stainless steel container to reduce the volume to l/8th of the original volume of water.
  • Loha obtained after bhanupaka was washed with hot water and placed in a sthali (Fe pan), to which above freshly prepared Triphala kwatha was added and intense heating was given for complete evaporation of water contents of Triphala kwatha.
  • Triphala kwatha was added and subjected to heat till dryness. It was further incinerated (Putapaka).
  • the dried earthen capsule containing the discs is subjected to heat using Gaja Puta (here, in a pit of 56.26x56.25x56.25 cubic cm, 250 cowdungs of standard size are filled; earthen capsule is placed on it. Vacant space is again filled with 125 cowdungs and lit with fire (here, specific quantum and pattern of heating is provided.). After self-cooling (cooling by itself, without any external aid), earthen saucer capsule is carefully collected, seal is removed, saucers separated and the material inside is collected. This cycle from grinding with decoction till heating is repeated atleast 30 times or till the Bhasma is properly prepared which is ascertained by specific tests.
  • Gaja Puta here, in a pit of 56.26x56.25x56.25 cubic cm, 250 cowdungs of standard size are filled; earthen capsule is placed on it. Vacant space is again filled with 125 cowdungs and lit with fire (here, specific quantum and pattern of heating is provided.).
  • self-cooling cooling by itself
  • Jarita Trivanga is added with water, macerated and allowed to settle down over night. The next day morning supernatant water is decanted. The procedure is repeated for 3 days till it attained the pH 7, it is necessitated to remove excess Kshara( alkali).
  • Jarita Trivanga is then performed. Jarita Trivanga is subjected to levigation with decoction mentioned in table 4D and juices mentioned in table 4E and when the mixture attain proper consistency, chakrikas(pellets/discs of 0.5x2.5cm dimension) are made and dried in hot air oven at 50°C. They are then placed in Sharavasamputa and subjected to Laghuputa (specific quantum of heat). The procedure was repeated for 16 times till all the characteristic features of Bhasma are obtained.
  • shodhana or Classical method of purification is performed.
  • pieces of coral are washed in demineralized water, dried in hot air oven at 50°C, wrapped by a clean, starch less cloth and tied into a bolus.
  • This bolus is suspended with the help of a thread from an iron rod placed at the inlet of an earthen pot.
  • Sarja Kshara (Barilla) dissolved in water is taken. Height of the bolus is maintained in such a way that it does not touch the base of the pot but remains immersed in the liquid throughout the procedure. Pot is heated at a temperature between 65 to 80°C for three hours. Then the cloth bolus is opened, purified coral is removed, washed with hot water and dried.
  • earthen saucer capsule After self-cooling (cooling by itself, without any external aid), earthen saucer capsule is carefully collected, seal is removed, saucers separated and the material inside is collected. The content inside the earthen saucer capsule is powdered and levigated with specified juice for about six hours till a soft homogenous paste is obtained.
  • the dough obtained is prepared into discs of 0.5cm thickness and 2.5 cm diameter. Discs are dried under Sun or /in hot air oven at 50 ° C. The dried discs are spread as a layer in an earthen saucer (Sharava). It is closed with another earthen saucer. The joint between the earthen saucers is sealed with mud plasters and dried to get a capsule (Sharava samputa). Dried earthen capsule containing the discs is subjected to heat using Gaja Puta. This cycle is repeated four times using different juice mentioned in Table 4F each time for levigation. After 4 such cycles of incineration Pravala Bhasma is formed.
  • complications associated with thyroid dysfunction shall include any condition generally known to be associated with thyroid function such as Hashimoto's thyroiditis, hyperthyroidism, hypothyroidism. Goiter, Thyrotoxicosis, Graves' disease, autoimmune thyroiditis, etc.
  • the embodiments disclosed herein also include a method of improving thyroid function in hyperthyroidic and hypolhyroidic conditions.
  • embodiments disclosed herein also include a method for treatment and management of thyroid disorders and symptoms associated with thyroid disorders such as Weight gain, Depression, Skin dryness, Hair fall, Fatigue, Acid eructation, Constipation, Weight loss, Anxiety, Sweating, Tremors, Palpitation, Hair fall, Sleep disturbance, Diarrhoea, etc.
  • embodiments disclosed herein also include methods for improving complications associated with thyroid dysfunction such as Lipid peroxidation (LPO) level, Superoxide Dismutase (SOD) activity, lipid profile (HDL, LDL and Triglycerides levels), C reactive protein (CRP) level, blood glucose, Catalase activity. Glutathione level, T3, T4, TSH levels, etc.
  • the method includes administering a patient with the composition as described in any of the embodiments disclosed herein.
  • the patient may include any individual in need of such treatment including but not limited to individuals having Thyroid dysfunction, and disorders or any complications generally known to be associated with thyroid dysfunction such as Hashimoto's thyroiditis, hyperthyroidism, hypothyroidism, Goiter, Thyrotoxicosis, Graves' disease, autoimmune thyroiditis, etc.
  • the patient may further include any individual looking to improving thyroid function.
  • the patient may also be any individual having complications associated with other organs such as hypothalamus and pituitary glands, thereby resulting in thyroid hormone imbalance.
  • the patient may also include individuals having symptoms associated with thyroid disorders. Individuals prone to pre-natal or post-natal thyroid dysfunction may also be considered as suitable candidates for treatment by the disclosed embodiments.
  • the method includes administering to a patient a composition having Bauhinia variegata (10 to 14 wt%), Crataeva nurvala (10 to 14 wt%) and Commiphora mukul (8 to 12 wt%); atleast one of Emblica officinalis ( 2 to 6 wt%), Terminalia chebula ( ⁇ 3wt%), Terminalia bellerica ( ⁇ 3wt%), Zingiber officinale ( ⁇ 3wt%), Piper nigrum ( ⁇ 3wt%), Piper longum ( ⁇ 3wt%), Cinnamomum zeylanica ( ⁇ 3wt%), Elettaria cardamomum ( ⁇ 3wt%), Cinnamomum tamala ( ⁇ 3wt%), Glycerrhiza glabra ( ⁇ 3wt%), Boerhavia diffusa ( ⁇ 3wt%), Adhtatoda vasica ( ⁇ 3
  • the patient may be any individual in need of such treatment including ones having/ suspected of having Thyroid dysfunction and associated complications.
  • the patient may be any individual having/ suspected of having complications associated with Thyroid such as Hypothroidism, Autoimmune thyroiditis Eg. Hashimoto's Thyroiditis, etc.
  • the patient may also be any individual having/ suspected of having complications associated with other organs such as hypothalamus and pituitary glands, thereby resulting in thyroid hormone imbalance.
  • the disclosed composition may also be used to prevent Thyroid dysfunction and associated complications.
  • the patient may be administered a therapeutically effective amount of the embodiments of the disclosed composition.
  • the therapeutically effective amount may vary depending on the patient.
  • the therapeutically effective amount is 500 to 1000 mg administered one to three times a day.
  • Embodiments of the disclosed composition also referred as Test drug or product
  • Test drug was evaluated for toxicity as per OECD guidelines. Test drug was administered once orally to overnight fasted female Wistar rats at 2000 and 5000mg/kg body weight (2 steps / dose; 3 animals / step) at a dose volume 10 ml/kg. Body weight was recorded on day 0, 7 and 14. Mortality / Clinical signs were observed at approximately 30 minutes, 1, 2 and 4 h on day 0 (after test drug administration) and thereafter once daily for 14 days.
  • the LD50 value of "Test drug” was found to be greater than 5000 mg/kg body weight and classified as Category-5 or unclassified based on Globally Harmonised Classification System (GHS) for Chemical Substances and Mixtures.
  • GHS Globally Harmonised Classification System
  • the Test drug was evaluated clinically among 12 patients of Autoimune thyroiditis. Seven patients were presented with the features of hypothyroidism and remaining five patients were of hypothyroidism. Patients were evaluated for the improvement in clinical features, thyroid function tests (comprising of T3, T4 and TSH) and also oxidative stress parameters including lipid peroxidation (LPO), reduced glutathione content (GSH), superoxide dismutase (SOD) and catalase activity (CAT).
  • LPO lipid peroxidation
  • GSH reduced glutathione content
  • SOD superoxide dismutase
  • CAT catalase activity
  • present findings revealed decrease in LPO level and increase in level of GSH, SOD and CAT activity by the treatment of Test drug, indicating reduction in oxidative stress in hypothyroid and hyperthyroid state.
  • the Test drug is useful in management of both hypothyroidism and hyperthyroidism, and its primary mode of action looks to be anti-oxidant effect.
  • Dosage and duration Tablet Test drug was administered at a dose of 2 tablets twice daily after food by swallowing with water as Anupana. Evaluation was done after three months medication.
  • Lipid peroxidation assay For determination of lipid peroxidation (LPO), the blood was withdrawn from retro-orbital plexus and was taken in the centrifuge tube containing anticoagulant. From this 5% suspension of RBC in 0.1 M phosphate buffered saline was prepared. To 2 ml of this 5% suspension, 2 ml of 28% trichloroacetic acid was added and centrifuged. After centrifugation the supernatant was separated. To 4 ml of supernatant 1 ml of 1% thiobarbituric acid was added, heated in boiling water for 60 minutes and cooled immediately. The absorbance was measured spectrophotometrically at 532 nm. The lipid peroxidation was calculated on the basis of the molar extinction coefficient of malondialdehyde (MDA) (1.56 x 105) and expressed in terms of nanomoles of MDA/g Hb.
  • MDA malondialdehyde
  • Reduced glutathione assay Glutathione activity was measured in whole blood.
  • the blood (0.2 ml) was added to 1.8 ml of distilled water followed by 3.0 ml of precipitating mixture (1.67gms of metaphorsphoric acid, 0.2gms of EDTA, 30gms NaCl to make 100 ml of solution). It was centrifuged at 2000 rpm for 5 minutes. Supernatant (1 ml) was added to 1.5 ml of phosphate solution followed by addition of 0.5 ml of DTNB reagent. The optical density was measured at 412 nm using spectrophotometer.
  • Catalase assay The activity of catalase enzyme was determined in erythrocyte lysate. The lysate (50 ml) was taken and added to a test tube containing 2 ml of phosphate buffer (pH 7.0) and then 1 ml of 30 mM of H202 was added to it. The decrease in absorbance was measured at 240 nm for 1 minute using spectrophotometer.
  • Clinical parameters These parameters were studied before and after the regimen of Test drug and the results are shown hereunder. Hypothyroid and hyperthyroid patients exhibited the symptoms like anxiety, depression, acidity, constipation etc. These patients showed significant reversal in the symptoms after the treatment with Test drug. Tables 5 depicts the effects of Test drug on clinical features of Hypothyroidism.
  • Tables 6 depicts the effects of Test drug on clinical features Hyperthyroidism.
  • Thyroid function tests TSH level in hypothyroidism patients showed a marked reduction from 12.55 to 3.25 on an average. These patients however had normal T3 and T4 levels. Among the patients of hyperthyroidism average TSH level was significantly improved along with corresponding changes in T3 and T4 levels. Tables 7 depicts the results of Thyroid test function in Hypothyroidism.
  • Table 8 depicts the results of Thyroid test function in Hyperthyroidism.
  • Lipid peroxidation assay In normal control group the LPO levels (0.8339 + 0.1361) showed insignificant decrease in Test drug treated control group; whereas in hypothyroid and hyperthyroid group, the LPO levels (6.819 + 0.8946) and (10.17 + 0.9115) respectively showed significant decrease with the treatment of Test drug. The results are depicted in the table provided hereunder. Thus, the marked increase in the oxidative stress was found in hypothyroid and hyperthyroid groups as indicated by increase in LPO levels, whereas treatment with Test drug showed reduction in oxidative stress. Table 9 depicts the effect of Test drug on Lipid peroxidation level.
  • Catalase assay In normal control group the CAT activity (2.928 + 0.7428) showed insignificant increase in Test drug treated control group; whereas in hypothyroid and hyperthyroid groups, the CAT activity (0.3709 + 0.1193) and (0.2296 + 0.0923) showed significant increase with the treatment of Test drug. The results are depicted in the table provided hereunder. Thus, the marked increase in the oxidative stress was found in hypothyroid and hyperthyroid groups as indicated by decrease in CAT activity, whereas treatment with Test drug showed decrease in oxidative stress as indicated by the increased CAT activity as compared to hypothyroid and hyperthyroid groups. Table 12 depicts the effect of Test drug on Catalase activity.
  • Table 13 depicts the effect of Test drug on lipid profile, CRP and blood glucose parameters. [00123] Table 13:
  • Table 14 depicts the Safety evaluation of test drugs on hepatic and renal parameters

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'Invention concerne une composition à base d'herbes pour le traitement et la gestion d'un dysfonctionnement de la thyroïde et un procédé de préparation. La composition de l'invention comprenant des herbes et Des bhasmas peut être utilisée pour traiter Un dysfonctionnement de la Thyroïde et des complications associées telles Que La thyroïdite de Hashimoto, l'hyperthyroïdie, l'hypothyroïdie, le goitre, la thyrotoxicose, la maladie de Graves, la thyroïdite auto-immune, etc. Le procédé de l'invention peut être utilisé comme ligne principale de traitement ou comme médicament de soutien.
PCT/IN2018/050691 2017-10-31 2018-10-26 Composition à base d'herbes pour le traitement et la gestion d'un dysfonctionnement de la thyroïde et son procédé de préparation Ceased WO2019087207A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741038745 2017-10-31
IN201741038745 2017-10-31

Publications (2)

Publication Number Publication Date
WO2019087207A2 true WO2019087207A2 (fr) 2019-05-09
WO2019087207A3 WO2019087207A3 (fr) 2019-07-11

Family

ID=66331530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2018/050691 Ceased WO2019087207A2 (fr) 2017-10-31 2018-10-26 Composition à base d'herbes pour le traitement et la gestion d'un dysfonctionnement de la thyroïde et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2019087207A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147459A1 (en) * 2002-10-23 2004-07-29 Joseph Oneal Method and composition for maintaining urinary tract health in the face of infections
IL184312A0 (en) * 2007-06-28 2008-01-20 Ascarit Ltd Herbal compositions for the treatment of diabetes and/or conditions associated therewith
US8067043B2 (en) * 2008-04-17 2011-11-29 Sahajanand Biotech Pvt. Ltd. Herbal composition for treatment of hyperlipidemia and the inhibition of myocardial infarction
TWI631955B (zh) * 2015-11-05 2018-08-11 中央研究院 羊蹄甲屬萃取物及其用途

Also Published As

Publication number Publication date
WO2019087207A3 (fr) 2019-07-11

Similar Documents

Publication Publication Date Title
US11045512B2 (en) Herbal composition for the treatment and management of Thyroid dysfunction and method of preparation thereof
US10576117B2 (en) Herbo-mineral formulation for prevention, treatment and management of diabetes and method of preparation thereof
US10675322B2 (en) Herbal formulation for management of metabolic disorders and method of preparation thereof
Rahman et al. Scientific appraisal of Unani concept of islah-e-advia (rectification/purification of drugs) and its importance
US11433111B2 (en) Composition for treatment and management of dementia and cognitive dysfunction and method of preparation thereof
WO2020115775A1 (fr) Composition pour le traitement et la gestion de la démence et d'un dysfonctionnement cognitif et son procédé de préparation
CN110882309A (zh) 一种治疗鸡滑液囊支原体病的中药组合物及其制备方法
CN103230486B (zh) 一种中药组合物及其制备方法以及在制备治疗脂肪肝药物中的应用
WO2019087207A2 (fr) Composition à base d'herbes pour le traitement et la gestion d'un dysfonctionnement de la thyroïde et son procédé de préparation
CN110721289A (zh) 仁术健胃颗粒的制备方法
Alam et al. Therapeutic use of Withania somnifera
Samant et al. Significance ofParad in Rasashastra-A review
US11141447B2 (en) Composition for treatment and management of addiction and method of preparation thereof
WO2018211527A1 (fr) Formulation à base d'herbes pour la prise en charge de troubles métaboliques et son procédé de préparation
CN116370526A (zh) 一种用于调理便秘的超微粉及其药物
WO2020225609A1 (fr) Composition herbo-minérale métallique pharmaceutique et sa méthode de préparation
US12589129B2 (en) Polyherbal metallo-mineral pharmaceutical kit
Rajkumar et al. Basic Principles in Siddha Pharmaceutical Science-An Overview
WO2020044372A1 (fr) Composition pour le traitement et la gestion de la dépendance et son procédé de préparation
CN104958666A (zh) 妇科再造口服制剂的制备方法
US20200197477A1 (en) Composition for treatment and management of Polycystic ovarian syndrome and method of preparation thereof
CN113893316B (zh) 中药组合物在制备改善湿热质人群的慢性疲劳症状的药物中的应用
TWI403328B (zh) 具有調節血脂功能之中草藥油溶性萃取物
Ahmad Physicochemical, Analytical and Toxicity Studies on Kushta Khabasul Hadeed (Calx of Iron Rust) Prepared by Two Methods
AU2021104091A4 (en) Polyherbal capsule as a potential detoxification agent.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18874481

Country of ref document: EP

Kind code of ref document: A2